

Allen R Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4829372/publications.pdf>

Version: 2024-02-01

88
papers

5,706
citations

172457

29
h-index

76900

74
g-index

90
all docs

90
docs citations

90
times ranked

5997
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of Electronic Communication of Medication Discontinuation (CancelRx) on Medication Safety: A Pilot Study. <i>Journal of Patient Safety</i> , 2022, 18, e934-e937.	1.7	3
2	Trainee-led Engagement of the Care Team Improves Application of an Institutional Blood Culture Clinical Decision Algorithm to Pediatric Oncology Inpatients: A Single-institution Quality Improvement Project. <i>Pediatric Quality & Safety</i> , 2022, 7, e545.	0.8	2
3	Barriers in communicating medication changes at hospital discharge: Informing CancelRx design requirements. <i>Journal of Patient Safety and Risk Management</i> , 2021, 26, 99-103.	0.6	3
4	Microbial Sharing between Pediatric Patients and Therapy Dogs during Hospital Animal-Assisted Intervention Programs. <i>Microorganisms</i> , 2021, 9, 1054.	3.6	9
5	Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed <i>ALK</i> F1174L-mutated neuroblastoma. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006064.	1.2	16
6	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. <i>Blood Advances</i> , 2020, 4, 3913-3925.	5.2	52
7	Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. <i>Nature Medicine</i> , 2020, 26, 529-534.	30.7	87
8	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019, 3, 3393-3405.	5.2	81
9	Understanding CancelRx: Results of End-to-End Functional Testing, Proactive Risk Assessment, and Pilot Implementation. <i>Applied Clinical Informatics</i> , 2019, 10, 336-347.	1.7	13
10	Automated E-mail Reminders Linked to Electronic Health Records to Improve Medication Reconciliation on Admission. <i>Pediatric Quality & Safety</i> , 2018, 3, e109.	0.8	6
11	A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. <i>Clinical Sarcoma Research</i> , 2018, 8, 21.	2.3	22
12	Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2040-2046.	2.0	29
13	A Model for the Departmental Quality Management Infrastructure Within an Academic Health System. <i>Academic Medicine</i> , 2017, 92, 608-613.	1.6	14
14	Electrophysiological effects of anthracyclines in adult survivors of pediatric malignancy. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26556.	1.5	25
15	Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2127-2136.	2.0	17
16	Tolerance and effectiveness of nivolumab after pediatric Tâ€cell replete, haploidentical, bone marrow transplantation: A case report. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26257.	1.5	22
17	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 325-332.	2.0	61
18	Quality and Safety in Hematopoietic Stem Cell Transplant Patients. , 2017, , 297-324.		0

#	ARTICLE	IF	CITATIONS
19	Automated Functional Imaging by 2D Speckle Tracking Echocardiography Reveals High Incidence of Abnormal Longitudinal Strain in a Cohort of Pediatric Oncology Patients. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1075-1080.	1.5	8
20	Persistent Multiyear Control of Relapsed Tâ€Cell Acute Lymphoblastic Leukemia With Successive Donor Lymphocyte Infusions: A Case Report. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1279-1282.	1.5	5
21	High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 627-635.	0.6	11
22	Improved Behavior and Neuropsychological Function in Children With ROHHAD After High-Dose Cyclophosphamide. <i>Pediatrics</i> , 2016, 138, .	2.1	30
23	Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 895-901.	2.0	64
24	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigenâ€Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 112-118.	2.0	37
25	Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMT, the I-BFM and the Westhafen-Intercontinental-Group. <i>Blood</i> , 2016, 128, 985-985.	1.4	2
26	Hepatopulmonary Syndrome Is a Frequent Cause of Dyspnea in the Short Telomere Disorders. <i>Chest</i> , 2015, 148, 1019-1026.	0.8	95
27	Bringing Central Lineâ€Associated Bloodstream Infection Prevention Home: Catheter Maintenance Practices and Beliefs of Pediatric Oncology Patients and Families. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2015, 41, 177-AP4.	0.7	10
28	Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Bone Marrow Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Largest Reported Experience with High Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S29.	2.0	9
29	Pain Management for Children during Bone Marrow and Stem Cell Transplantation. <i>Pain Management Nursing</i> , 2015, 16, 156-162.	0.9	22
30	HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 314-318.	2.0	103
31	Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1033-1039.	2.0	17
32	Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031. <i>Journal of Clinical Oncology</i> , 2014, 32, 3651-3658.	1.6	200
33	Feasibility of Treating Post-Transplantation Minimal Residual Disease in Children with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1000-1007.	2.0	9
34	WT1 regulates angiogenesis in Ewing Sarcoma. <i>Oncotarget</i> , 2014, 5, 2436-2449.	1.8	32
35	Central Line Maintenance Bundles and CLABSI in Ambulatory Oncology Patients. <i>Pediatrics</i> , 2013, 132, e1403-e1412.	2.1	58
36	Ambulatory pediatric oncology CLABSI: Epidemiology and risk factors. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1882-1889.	1.5	55

#	ARTICLE	IF	CITATIONS
37	Bringing Central Line–Associated Bloodstream Infection Prevention Home: CLABSI Definitions and Prevention Policies in Home Health Care Agencies. Joint Commission Journal on Quality and Patient Safety, 2013, 39, 361-AP5.	0.7	23
38	The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy). Blood, 2013, 122, 4629-4629.	1.4	1
39	Implementation of a Central Line Maintenance Care Bundle in Hospitalized Pediatric Oncology Patients. Pediatrics, 2012, 130, e996-e1004.	2.1	97
40	Body Composition After Bone Marrow Transplantation in Childhood. Oncology Nursing Forum, 2012, 39, 186-192.	1.2	18
41	Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation. Blood, 2012, 120, 4205-4205.	1.4	14
42	Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation. Blood, 2012, 120, 4206-4206.	1.4	0
43	Cyclophosphamide for Rapid-Onset Obesity, Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome. Journal of Pediatrics, 2011, 158, 337-339.	1.8	46
44	Emergent Complications in the Pediatric Hematopoietic Stem Cell Transplant Patient. Clinical Pediatric Emergency Medicine, 2011, 12, 233-244.	0.4	9
45	Computerized Provider Order Entry in Pediatric Oncology: Design, Implementation, and Outcomes. Journal of Oncology Practice, 2011, 7, 218-222.	2.5	30
46	Myeloablative Haploidentical Bone Marrow Transplantation with T Cell Replete Grafts and Post-Transplant Cyclophosphamide: Results of a Phase II Clinical Trial,. Blood, 2011, 118, 4151-4151.	1.4	11
47	High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood, 2010, 115, 2136-2141.	1.4	107
48	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood, 2010, 115, 3224-3230.	1.4	346
49	Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood, 2010, 116, 4007-4015.	1.4	105
50	Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer, 2010, 116, 5470-5478.	4.1	27
51	Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome. Biology of Blood and Marrow Transplantation, 2010, 16, 157-168.	2.0	509
52	Advancement of Pediatric Blood and Marrow Transplantation Research in North America: Priorities of the Pediatric Blood and Marrow Transplant Consortium. Biology of Blood and Marrow Transplantation, 2010, 16, 1212-1221.	2.0	11
53	Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial. Biology of Blood and Marrow Transplantation, 2010, 16, 1005-1017.	2.0	227
54	Bone Mineral Density after Bone Marrow Transplantation in Childhood: Measurement and Associations. Biology of Blood and Marrow Transplantation, 2010, 16, 1451-1457.	2.0	22

#	ARTICLE	IF	CITATIONS
55	Sustained first remission in an adolescent with hepatosplenic Tâ€cell lymphoma treated with Tâ€cell leukemia induction, nucleoside analogâ€based consolidation, and early hematopoietic stem cell transplant. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1127-1129.	1.5	13
56	Evaluation of Quality Improvement Initiative in Pediatric Oncology. <i>Journal of Nursing Care Quality</i> , 2009, 24, 153-159.	0.9	9
57	A Clinical Algorithm Identifies High Risk Pediatric Oncology and Bone Marrow Transplant Patients Likely to Benefit From Treatment of Adenoviral Infection. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 825-831.	0.6	20
58	RBC transfusion and BMT rejection. <i>Blood</i> , 2009, 114, 2209-2210.	1.4	6
59	Successful treatment of a child with late onset T-cell post-transplant lymphoproliferative disorder/lymphoma. <i>Pediatric Blood and Cancer</i> , 2008, 50, 667-670.	1.5	24
60	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 641-650.	2.0	1,525
61	Phase II Study of Pentostatin in Patients With Corticosteroid-Refractory Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2007, 25, 4255-4261.	1.6	84
62	Treatment of hepatitisâ€associated aplastic anemia with highâ€dose cyclophosphamide. <i>Pediatric Blood and Cancer</i> , 2007, 49, 947-951.	1.5	21
63	The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. <i>Blood</i> , 2006, 107, 4695-4702.	1.4	46
64	Failure of intravenous pentamidine prophylaxis to prevent pneumocystis pneumonia in a pediatric hematopoietic stem cell transplant (HSCT) patient. <i>Pediatric Blood and Cancer</i> , 2006, 47, 859-860.	1.5	13
65	Error Reduction in Pediatric Chemotherapy. <i>JAMA Pediatrics</i> , 2006, 160, 495.	3.0	123
66	Treatment of Hepatitis-Associated Aplastic Anemia with High Dose Cyclophosphamide.. <i>Blood</i> , 2006, 108, 975-975.	1.4	0
67	Clinical effects of scaling and root planing on untreated teeth. <i>Journal of Clinical Periodontology</i> , 2005, 32, 21-28.	4.9	20
68	Bone marrow transplantation for sickle cell anemia: Progress and prospects. <i>Pediatric Blood and Cancer</i> , 2005, 44, 436-440.	1.5	26
69	Pentostatin in Steroid-Refractory Chronic Graft-Versus-Host Disease.. <i>Blood</i> , 2005, 106, 1805-1805.	1.4	4
70	Cyclosporine, Interferon-Î³, and Interleukin-2 Immunotherapy Is Tolerable and Induces Autoreactivity in Patients with Recurrent/Refractory Hodgkin Disease Undergoing Autologous Stem Cell Transplantation with BEAM: A COG Study.. <i>Blood</i> , 2005, 106, 2087-2087.	1.4	0
71	Pentostatin â€“ pharmacology, immunology, and clinical effects in graft-versus-host disease. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2605-2613.	1.8	8
72	Autologous Hematopoietic Stem-Cell Transplantation for Children With Acute Myeloid Leukemia in First or Second Complete Remission: A Prognostic Factor Analysis. <i>Journal of Clinical Oncology</i> , 2004, 22, 3798-3804.	1.6	21

#	ARTICLE	IF	CITATIONS
73	High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. <i>Experimental Hematology</i> , 2004, 32, 435-440.	0.4	43
74	Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 655-668.	2.0	71
75	Pentostatin: Efficacy in Refractory Chronic GVHD in Children.. <i>Blood</i> , 2004, 104, 2249-2249.	1.4	1
76	Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β^0 -thalassemia. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 519-528.	2.0	253
77	Novel Translocation in Acute Megakaryoblastic Leukemia (AML-M7). <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 396-402.	0.6	5
78	Pentostatin for the Treatment of Chronic Graft-Versus-Host Disease in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 584-588.	0.6	44
79	Misinterpretation of a Calvert-Derived Formula Leading to Carboplatin Overdose in Two Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 818-821.	0.6	10
80	Commentary on "Summary of Symposium: The Future of Stem Cell Transplantation for Sickle Cell Disease". <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 515-517.	0.6	1
81	Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. <i>Blood</i> , 2002, 100, 4337-4343.	1.4	328
82	Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - An American view. <i>British Journal of Haematology</i> , 2002, 118, 378-384.	2.5	44
83	Fatal Warm Autoimmune Hemolytic Anemia Resulting From IgM Autoagglutinins in an Infant With Severe Combined Immunodeficiency. <i>The American Journal of Pediatric Hematology/oncology</i> , 2001, 23, 250-252.	1.3	23
84	High-dose therapy with stem cell rescue for pediatric solid tumors: Rationale and results. <i>Pediatric Transplantation</i> , 1999, 3, 78-86.	1.0	10
85	Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. <i>Journal of Pediatric Surgery</i> , 1999, 34, 112-116.	1.6	37
86	Immune constitution of complete DiGeorge anomaly by transplantation of unmobilised blood mononuclear cells. <i>Lancet, The</i> , 1998, 352, 1983-1984.	13.7	26
87	Lipopolysaccharide exposure during purification of human monocytes by adherence increases their recovery and cytolytic activity. <i>Cellular Immunology</i> , 1986, 103, 120-132.	3.0	3
88	Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors. , 0, , 985-1000.		0